Crystal structure of the T315I mutant of AbI kinase

Chemical Biology and Drug Design

Volumn 70, Issue 3, 2007, Pages 171-181

  Zhou, Tianjun ^a   Parillon, Lois ^a   Li, Feng ^a   Wang, Yihan ^a   Keats, Jeff ^a   Lamore, Sarah ^a   Xu, Qihong ^a   Shakespeare, William ^a   Dalgarno, David ^a   Zhu, Xiaotian ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

AbI; CML; Crystal structure; Drug resistance; Inhibitors; Mutation

Indexed keywords

5 [3 (2 METHOXYPHENYL) 1H PYRROLO[2,3 B]PYRIDIN 5 YL] N,N DIMETHYLPYRIDINE 3 CARBOXAMIDE; ABELSON KINASE; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; GLYCINE; IMATINIB; ISOLEUCINE; MUTANT PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; GENE MUTATION; HYDROPHOBICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; MICE; MODELS, MOLECULAR; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIDINES; STRUCTURAL HOMOLOGY, PROTEIN; THREONINE;

PYRONIA TITHONUS;

EID: 34548169642     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00556.x     Document Type: Article

References (41)

1. Clarkson B., Strife A., Wisniewski D., Lambek C.L., Liu C. (2003) Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 17 : 1211 1262.
2. Faderl S., Kantarjian H.M., Thomas D.A., Cortes J., Giles F., Pierce S., Albitar M., Estrov Z. (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36 : 263 273.
3. Hantschel O., Superti-Furga G. (2004) Regulation of the c-AbI and Bcr-AbI tyrosine kinases. Nat Rev Mol Cell Biol 5 : 33 44.
4. Sawyers C.L. (1999) Chronic myeloid leukemia. N Engl J Med 340 : 1330 1340.
5. Wong S., Witte O.N. (2004) The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22 : 247 306.
6. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 : 500 502.
7. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C. et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 : 2542 2551.
8. Melo J.V., Hughes T.P., Apperley J.F. (2003) Chronic myeloid leukemia. Hematol Am Soc Hematol Educ Program : 132 152.
9. Deininger M., Buchdunger E., Druker B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 : 2640 2653.
10. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1031 1037.
11. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. (2002) Crystal structures of the kinase domain of c-AbI in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 : 4236 4243.
12. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 : 1938 1942.
13. Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P., Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D., Manley P.W. (2007) Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 63 : 80 93.
14. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. (2003) Structural basis for the autoinhibition of c-AbI tyrosine kinase. Cell 112 : 859 871.
15. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 : 690 698.
16. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 : 876 880.
17. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., Tura S. et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 : 1965 1971.
18. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 : 399 401.
19. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., Schiffer C.A. et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 : 1928 1937.
20. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 : 117 125.
21. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S. et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/AbI kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 : 6658 6661.
22. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., Cowan-Jacob S.W., Lee F.Y., Heinrich M.C., Deininger M.W., Druker B.J. (2005) In vitro activity of Bcr-AbI inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant AbI kinase domain mutants. Cancer Res 65 : 4500 4505.
23. Kantarjian H., O'Brien S., Talpaz M., Borthakur G., Ravandi F., Faderl S., Verstovsek S., Rios M.B., Shan J., Giles F., Cortes J. (2007) Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109 : 1556 1560.
24. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7 : 345 356.
25. Ray A., Cowan-Jacob S.W., Manley P.W., Mestan J., Griffin J.D. (2007) Identification of Bcr/AbI point mutations conferring resistance to the AbI kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study. Blood 109 : 5011 5015.
26. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M., Miller K.M. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10 : 262 267.
27. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V. et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 : 11011 11016.
28. Arnold W.D., Bounaud P., Goserber A., Li Z., Mcdonald I., Steensma R.W., Wilson M.E. (2006) Pyrrolo-pyridine kinase modulators. Patent WO 2006/015123 A1 : 1 226.
29. Seeliger M.A., Young M., Henderson M.N., Pellicena P., King D.S., Falick A.M., Kuriyan J. (2005) High yield bacterial expression of active c-AbI and c-Src tyrosine kinases. Protein Sci 14 : 3135 3139.
30. Otwinowski Z., Minor W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276 : 307 326.
31. Navaza J. (1994) AMoRe: an automated package for molecular replacement. Acta Crystallogr A 50 : 157 163.
32. Hubbard S.R., Mohammadi M., Schlessinger J. (1998) Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 273 : 11987 11990.
33. Johnson L.N., Noble M.E., Owen D.J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85 : 149 158.
34. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. (1997) Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90 : 859 869.
35. Dunbrack R.L. Jr., Cohen F.E. (1997) Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci 6 : 1661 1681.
36. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., Klei H.E. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 : 5790 5797.
37. Derewenda Z.S., Lee L., Derewenda U. (1995) The occurrence of C-H.O hydrogen bonds in proteins. J Mol Biol 252 : 248 262.
38. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., Biggs W.H. III., Treiber D.K., Patel H.K., Zarrinkar P.P., Lockhart D.J., Sawyers C.L., Kuriyan J. (2006) Structure of the kinase domain of an imatinib-resistant AbI mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66 : 1007 1014.
39. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49 : 6177 6196.
40. Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R., Horne E.L., Kadwell S.H., McKee D.D., Moore J.T. (2000) Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8 : 1105 1113.
41. Daub H., Specht K., Ullrich A. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3 : 1001 1010.